https://orcid.org/0000-0002-8175-0553
References
- Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. JAMA Neurol. 2018 Mar 1;75(3):279–286.
- Barker-Haliski ML, White HS. Antiepileptic drug development and experimental models. In: Wyllie E, editor. Wyllie’s treatment of epilepsy: principles and practice: sixth edition. 6th ed. Philadelphia: Wolters Kluwer Health; 2015. p. 516–521.
- Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998 Jul 24;353(2–3):191–206.
- Potschka H, Loscher W. Corneal kindling in mice: behavioral and pharmacological differences to conventional kindling. Epilepsy Res. 1999;37(2):109–120.
- Klein P, Dingledine R, Aronica E, et al. Commonalities in epileptogenic processes from different acute brain insults: do they translate? Epilepsia. 2018 Jan;59(1):37–66. Epub 2017 Dec 15.
- Kehne JH, Klein BD, Raeissi S, et al. The national institute of neurological disorders and stroke (NINDS) epilepsy therapy screening program (ETSP). Neurochem Res. 2017 Jul;42(7):1894–1903.
- Vezzani A, Friedman A, Dingledine RJ. The role of inflammation in epileptogenesis. Neuropharmacology. 2013 Jun;69:16–24.
- Matagne A, Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 1998 Jun;31(1):59–71.
- Rowley NM, White HS. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res. 2010 Dec;92(2–3):163–169.
- Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia. 2001;42(Suppl 4):13–18.
- Koneval Z, Knox KM, White HS, et al. Lamotrigine-resistant corneal-kindled mice: A model of pharmacoresistant partial epilepsy for moderate-throughput drug discovery. Epilepsia. 2018 Jun;59(6):1245–1256.
- Loewen JL, Barker-Haliski ML, Dahle EJ, et al. Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe epilepsy. J Neuropathol Exp Neurol. 2016 Apr;75(4):366–378.
- Albertini G, Walrave L, Demuyser T, et al. 6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain. Epilepsia. 2018 Jan;59(1):67–78.
- Krueger J, Berg AT. Incidence of dravet syndrome in a US population. Pediatr Neurol Briefs. 2015 Dec;29(12):92.
- Kaplan JS, Stella N, Catterall WA, et al. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11229–11234.
- Patra PH, Barker-Haliski M, White HS, et al. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 2019 Feb;60(2):303–314.
- Leppik IE. Treatment of Epilepsy in the Elderly. Epilepsy Curr. 2001 Nov;1(2):46–47.
- Lam AD, Deck G, Goldman A, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer’s disease. Nat Med. 2017 Jun;23(6):678–680.